Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the lower limit of detection (LLOD), is associated with better clinical outcomes of ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

U.S. medical centers have appealed to the FDA for compassionate use approval of the adenosine receptor inhibitor namodenoson for pancreatic cancer, according to Can-Fite BioPharma. About 85% of ...

Candidate Genes in Canine Hepatocellular Carcinoma for Molecular Targeted ... team has identified a crucial link between a gene mutation and immune system signaling in canine hemangiosarcoma ...

Statins appeared to reduce the risk for hepatocellular carcinoma and hepatic decompensation among patients with chronic liver disease, according to findings in JAMA Internal Medicine.

On April 11, the FDA approved the combination of Opdivo and Yervoy for treating advanced cases of hepatocellular carcinoma ... a known acquired resistance mutation. The drug received accelerated ...

The company’s lead candidate, ELI-002, targets KRAS mutations, found in some ... vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.” In three patients, the ...

“This designation for the treatment of FAP underscores Tempest's mission to make a meaningful difference in the lives of patients and builds on the momentum from prior designations received for ...